Andrew I. Koven

2016

In 2016, Andrew I. Koven earned a total compensation of $5.8M as President and Chief Business Officer at Aralez Pharmaceuticals, a 52% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$337,500
Option Awards$87,277
Salary$450,000
Stock Awards$686,557
Other$4,229,174
Total$5,790,508

Koven received $4.2M in other compensation, accounting for 73% of the total pay in 2016.

Koven also received $337.5K in non-equity incentive plan, $87.3K in option awards, $450K in salary and $686.6K in stock awards.

Rankings

In 2016, Andrew I. Koven's compensation ranked 1,290th out of 14,075 executives tracked by ExecPay. In other words, Koven earned more than 90.8% of executives.

ClassificationRankingPercentile
All
1,290
out of 14,075
91st
Division
Manufacturing
433
out of 5,488
92nd
Major group
Chemicals And Allied Products
114
out of 1,900
94th
Industry group
Drugs
76
out of 1,543
95th
Industry
Pharmaceutical Preparations
61
out of 1,173
95th
Source: SEC filing on March 23, 2017.

Koven's colleagues

We found four more compensation records of executives who worked with Andrew I. Koven at Aralez Pharmaceuticals in 2016.

2016

Adrian Adams

Aralez Pharmaceuticals

Chief Executive Officer

2016

Scott Charles

Aralez Pharmaceuticals

Chief Financial Officer

2016

James Tursi

Aralez Pharmaceuticals

Chief Medical Officer

2016

Mark Glickman

Aralez Pharmaceuticals

Chief Commercial Officer

You may also like